PLRZ
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Polyrizon files a U.S. patent application to strengthen intellectual property protection around its intranasal drug-delivery platformOct 5, 2026
- Polyrizon enrolls the first patient in a U.S. clinical study of NASARIX (PL-14) allergy blockerSep 22, 2026
- Polyrizon reported successful NASARIX biocompatibility results, supporting progression to its first human clinical trialJul 2, 2026
- Polyrizon received notice of U.S. patent publication for its mucoadhesive drug delivery platformJun 17, 2026
- Polyrizon secured three U.S. clinical sites for the NASARIX trialJun 10, 2026